Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
Xiaolei Li1,2, Wenhui Song3, Changshun Shao1
1The First Affiliated Hospital of Soochow University and State Key Laboratory of Radiation Medicine and Radioprotection, Institutes for Translational Medicine, Soochow University, Suzhou, Jiangsu, 215123, China.
Abstract:
Checkpoint blockade-based immunotherapy offers new options and powerful weapons for the treatment of cancer, but its efficacy varies greatly among different types of cancer and across individual patients. Thus, the development of the right tools that can be used to identify patients who could benefit from this therapy is of utmost importance in order to maximize the therapeutic benefit, minimize risk of toxicities, and guide combination approaches. Multiple predictors have emerged that are based on checkpoint receptor ligand expression, tumor mutational burden, neoantigen and microsatellite instability, tumor-infiltrating immune cells, and peripheral blood biomarkers. In this review, we discuss the current state and progress of predictors as aids in checkpoint blockade-based immunotherapy in cancer.
Insights
Predicting cancer immunotherapy success is crucial. This review covers biomarkers like gene expression and immune cell infiltration to identify patients who will benefit from checkpoint blockade therapy.
Area of Science:
- Oncology
- Immunology
- Biomarker Discovery
Background:
- Checkpoint blockade immunotherapy is a powerful cancer treatment, but its effectiveness varies significantly across cancer types and individuals.
- Identifying patients likely to respond is essential for maximizing treatment benefits and minimizing toxicity.
Purpose of the Study:
- To review the current landscape and advancements in predictive biomarkers for checkpoint blockade immunotherapy in cancer.
- To highlight tools that aid in patient selection for immunotherapy and guide combination strategies.
Main Methods:
- Review of existing literature on predictive biomarkers for cancer immunotherapy.
- Analysis of various predictor types, including molecular and cellular markers.
- Discussion of emerging trends and future directions in biomarker development.
Main Results:
- Multiple predictors are emerging, focusing on checkpoint receptor ligand expression, tumor mutational burden, neoantigen and microsatellite instability, tumor-infiltrating immune cells, and peripheral blood biomarkers.
- These predictors aim to stratify patients for immunotherapy efficacy.
Conclusions:
- Predictive tools are vital for optimizing checkpoint blockade immunotherapy by enabling precise patient selection.
- Continued research into novel biomarkers will enhance the efficacy and safety of cancer immunotherapy.
More Related Videos
Related Concept Videos
Humoral Immune Responses
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Applications of GIS: Disaster Management and Emergency Response
Targeted Cancer Therapies
There are several types of targeted therapies against...
Neuromuscular Junction And Blockade
Cell-mediated Immune Responses


